LPL Financial LLC trimmed its holdings in shares of Encompass Health Co. (NYSE:EHC – Free Report) by 4.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 27,648 shares of the company’s stock after selling 1,355 shares during the quarter. LPL Financial LLC’s holdings in Encompass Health were worth $1,872,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. US Bancorp DE boosted its stake in shares of Encompass Health by 66.4% in the 1st quarter. US Bancorp DE now owns 9,336 shares of the company’s stock valued at $664,000 after buying an additional 3,725 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new position in shares of Encompass Health in the 1st quarter valued at about $318,000. PNC Financial Services Group Inc. boosted its stake in shares of Encompass Health by 10.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,750 shares of the company’s stock valued at $622,000 after buying an additional 834 shares during the period. Bank of Montreal Can lifted its stake in Encompass Health by 1.5% during the first quarter. Bank of Montreal Can now owns 11,340 shares of the company’s stock worth $806,000 after purchasing an additional 173 shares during the last quarter. Finally, Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in Encompass Health by 10.5% during the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,463 shares of the company’s stock worth $2,593,000 after purchasing an additional 3,477 shares during the last quarter. 92.66% of the stock is owned by institutional investors and hedge funds.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on EHC shares. Royal Bank of Canada restated an “outperform” rating and set a $83.00 target price on shares of Encompass Health in a research note on Thursday, September 28th. Mizuho lifted their price target on Encompass Health from $74.00 to $77.00 and gave the stock a “buy” rating in a research report on Thursday, August 3rd. Credit Suisse Group lifted their price target on Encompass Health from $76.00 to $80.00 and gave the stock an “outperform” rating in a research report on Friday, August 4th. Barclays lifted their price target on Encompass Health from $61.00 to $71.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 3rd. Finally, StockNews.com assumed coverage on Encompass Health in a report on Thursday, October 5th. They issued a “buy” rating on the stock. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $77.60.
Insider Activity at Encompass Health
In other Encompass Health news, CEO Mark J. Tarr sold 25,330 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $71.06, for a total transaction of $1,799,949.80. Following the transaction, the chief executive officer now owns 497,405 shares of the company’s stock, valued at approximately $35,345,599.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. In other Encompass Health news, CEO Mark J. Tarr sold 25,330 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $71.06, for a total transaction of $1,799,949.80. Following the transaction, the chief executive officer now owns 497,405 shares of the company’s stock, valued at approximately $35,345,599.30. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Elissa Joy Charbonneau sold 8,294 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $69.58, for a total value of $577,096.52. Following the completion of the sale, the insider now directly owns 23,081 shares in the company, valued at approximately $1,605,975.98. The disclosure for this sale can be found here. 1.90% of the stock is currently owned by company insiders.
Encompass Health Stock Performance
Shares of NYSE:EHC opened at $62.85 on Monday. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.27 and a quick ratio of 1.27. Encompass Health Co. has a 12 month low of $51.15 and a 12 month high of $72.06. The firm has a market capitalization of $6.30 billion, a PE ratio of 17.96, a P/E/G ratio of 1.32 and a beta of 1.00. The business has a 50-day moving average of $65.89 and a two-hundred day moving average of $65.83.
Encompass Health (NYSE:EHC – Get Free Report) last posted its earnings results on Friday, October 27th. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.09. Encompass Health had a return on equity of 18.25% and a net margin of 7.54%. The business had revenue of $1.21 billion during the quarter, compared to analyst estimates of $1.19 billion. During the same quarter last year, the firm earned $0.67 earnings per share. The company’s revenue for the quarter was up 10.8% compared to the same quarter last year. As a group, research analysts forecast that Encompass Health Co. will post 3.52 earnings per share for the current year.
Encompass Health Dividend Announcement
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, January 16th. Investors of record on Tuesday, January 2nd will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.95%. The ex-dividend date is Friday, December 29th. Encompass Health’s dividend payout ratio is currently 17.14%.
About Encompass Health
Encompass Health Corporation provides post-acute healthcare services in the United States. It provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.
- Five stocks we like better than Encompass Health
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- MarketBeat Week in Review – 11/6 – 11/10
- 3 Monster Growth Stocks to Buy Now
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest in Toy Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Encompass Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Encompass Health and related companies with MarketBeat.com's FREE daily email newsletter.